Financial HighlightsPromotor teamCatarina Maia, MBATarget MarketA suite of computationalscreening workflowsPartnersCenter ...
Upcoming SlideShare
Loading in …5
×

3rd Edition Track Finals: BSim2 poster

355 views

Published on

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
355
On SlideShare
0
From Embeds
0
Number of Embeds
2
Actions
Shares
0
Downloads
3
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

3rd Edition Track Finals: BSim2 poster

  1. 1. Financial HighlightsPromotor teamCatarina Maia, MBATarget MarketA suite of computationalscreening workflowsPartnersCenter for Neuroscience andCell BiologyUniversity of CoimbraMaria João Saraiva, PhDUniversity of PortoErnesto Freire, PhDJohns Hopkins UniversitySheena Radford, PhDUniversity of LeedsOur ApproachThe Problem- Drug R&D: high costs, long times- Dry out of the drug discoverypipelines- Ageing of World population- Increasing incidence ofneurodegenerative diseasesOur SolutionsProducts — First in pipelineNew drug candidates againsttransthyretin-related diseases:- Familial Amyloid Polyneuropathy (FAP)- Familial Amyloid Cardiomyopathy (FAC)- Senile Systemic Amyloidosis (SSA)Our Advantages- Higher specificity / efficacy- Lower toxicity and side-effects- Lower risks and costsSurfing chemical space to hit biological targetsAnti-FAP productsup toUS$1.2 billion/year*Estimated costs and revenuesin thousands of US DollarsOur Business ModelLicensing and joint-venture agreementswith strategic partners in Pharma andBiotech industriesSecured and required fundsin thousands of US Dollars(2012-2016)Competition*Based on the number of FAP patients andthe asking price for VYNDAQEL®Investment sought: US$2.8M NPV: US$6.9M Payback: 2.1 yearsCompound Company Discovery in vitroPoCin vivoPoCPreclinical PhaseIPhaseIIPhaseIIIMarketVYNDAQEL®Small moleculePfizerSOM0226Repositioned SOM Biotechmds84Small moleculePentraxinTherapeuticsISIS-TTRRXAntisenseISISPharmaceuticalsALN-TTR02siRNAAlnylamPharmaceuticalsasking price of US$150/patient/year+ MilestonesAT-06,09,12Small moleculeBSIM2Carlos J. V. Simões, PharmDRui M. M. Brito, PhD

×